Express Scripts’ (ESRX) “Buy” Rating Reaffirmed at Robert W. Baird

Robert W. Baird reiterated their buy rating on shares of Express Scripts (NASDAQ:ESRX) in a report released on Tuesday morning. Robert W. Baird currently has a $92.00 target price on the stock, up from their previous target price of $81.00.

Several other brokerages have also recently commented on ESRX. Evercore ISI assumed coverage on shares of Express Scripts in a research note on Thursday, January 4th. They issued an in-line rating and a $78.00 price objective for the company. BidaskClub upgraded shares of Express Scripts from a buy rating to a strong-buy rating in a research note on Friday, December 22nd. SunTrust Banks set a $86.00 price objective on shares of Express Scripts and gave the company a buy rating in a research note on Thursday, December 21st. Needham & Company LLC restated a hold rating on shares of Express Scripts in a report on Thursday, December 21st. Finally, Royal Bank of Canada set a $68.00 target price on shares of Express Scripts and gave the company a hold rating in a report on Friday, December 15th. Five analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $77.09.

Shares of Express Scripts (ESRX) traded up $0.78 during midday trading on Tuesday, hitting $80.87. 3,156,100 shares of the company traded hands, compared to its average volume of 4,370,000. The company has a debt-to-equity ratio of 0.86, a current ratio of 0.73 and a quick ratio of 0.61. Express Scripts has a 12-month low of $55.80 and a 12-month high of $81.75. The firm has a market capitalization of $45,360.00, a PE ratio of 13.43, a price-to-earnings-growth ratio of 0.89 and a beta of 0.87.

Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.90 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.90. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. The firm had revenue of $24.68 billion during the quarter, compared to analysts’ expectations of $25.68 billion. During the same quarter last year, the business earned $1.74 earnings per share. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. research analysts forecast that Express Scripts will post 7.04 earnings per share for the current fiscal year.

Express Scripts announced that its Board of Directors has approved a share repurchase program on Monday, December 18th that permits the company to buyback 45,000,000 shares. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

In other news, VP Glen D. Stettin sold 3,449 shares of Express Scripts stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $81.00, for a total transaction of $279,369.00. Following the completion of the sale, the vice president now directly owns 33,715 shares in the company, valued at $2,730,915. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Christine Houston sold 10,104 shares of Express Scripts stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $70.08, for a total transaction of $708,088.32. Following the sale, the vice president now owns 87,400 shares of the company’s stock, valued at $6,124,992. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,644 shares of company stock valued at $1,289,609. Insiders own 0.68% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Burt Wealth Advisors grew its holdings in Express Scripts by 11.4% in the second quarter. Burt Wealth Advisors now owns 1,696 shares of the company’s stock valued at $108,000 after purchasing an additional 174 shares during the period. Bank of Nova Scotia Trust Co. purchased a new stake in Express Scripts in the third quarter valued at approximately $120,000. Monroe Bank & Trust MI grew its holdings in Express Scripts by 74.8% in the third quarter. Monroe Bank & Trust MI now owns 2,266 shares of the company’s stock valued at $156,000 after purchasing an additional 970 shares during the period. Capstone Investment Advisors Netherlands B.V. grew its holdings in Express Scripts by 49.3% in the second quarter. Capstone Investment Advisors Netherlands B.V. now owns 2,797 shares of the company’s stock valued at $179,000 after purchasing an additional 924 shares during the period. Finally, Nelson Roberts Investment Advisors LLC purchased a new stake in Express Scripts in the third quarter valued at approximately $193,000. Hedge funds and other institutional investors own 88.28% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/express-scripts-esrx-buy-rating-reaffirmed-at-robert-w-baird.html.

Express Scripts Company Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply